ArticleLeukemia2020

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.

F Heidel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.